Back to Search Start Over

Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study

Authors :
Helge Hebestreit
Cornelia Zeidler
Christopher Schippers
Martina de Zwaan
Jürgen Deckert
Peter Heuschmann
Christian Krauth
Monika Bullinger
Alexandra Berger
Mark Berneburg
Lilly Brandstetter
Anna Deibele
Jan Dieris-Hirche
Holm Graessner
Harald Gündel
Stephan Herpertz
Gereon Heuft
Anne-Marie Lapstich
Thomas Lücke
Tim Maisch
Christine Mundlos
Andrea Petermann-Meyer
Susanne Müller
Stephan Ott
Lisa Pfister
Julia Quitmann
Marcel Romanos
Frank Rutsch
Kristina Schaubert
Katharina Schubert
Jörg B. Schulz
Susann Schweiger
Oliver Tüscher
Kathrin Ungethüm
Thomas O. F. Wagner
Kirsten Haas
ZSE-DUO working group
Source :
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-12 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677 .

Details

Language :
English
ISSN :
17501172
Volume :
17
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Orphanet Journal of Rare Diseases
Publication Type :
Academic Journal
Accession number :
edsdoj.133f2dc7c254cdaa0e70f98011f467c
Document Type :
article
Full Text :
https://doi.org/10.1186/s13023-022-02176-1